查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870945

按疗法、疾病、最终用户和给药途径分類的郁血性心臟衰竭市场—2025-2032年全球预测

Congestive Heart Failure Market by Treatment Type, Disease Type, End User, Delivery Methods - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，郁血性心臟衰竭市场将成长至 96.2 亿美元，复合年增长率为 7.60%。

关键市场统计数据
基准年 2024 53.5亿美元
预计年份：2025年 57.3亿美元
预测年份 2032 96.2亿美元
复合年增长率 (%) 7.60%

从策略层面建构郁血性心臟衰竭的临床、技术和政策驱动因素框架，以塑造短期至中期内的治疗路径和相关人员的优先事项。

郁血性心臟衰竭仍是临床医师、医疗系统和创新者面临的核心挑战，亟需整合临床、技术和政策因应措施。药理学、器材治疗和外科技术的进步正与数位医疗和远距监测相结合，从而改变不同医疗机构中患者的诊断、分层和管理方式。同时，支付方的期望和日益严格的监管要求相关人员在实际疗效和成本效益的基础上，证明其临床获益。本文阐述了临床背景，重点介绍了核心技术和治疗层级，并提出了领导者为实现更佳治疗效果必须应对的策略挑战框架。

本文对正在重塑心臟衰竭治疗患者路径和商业性需求的治疗、数位化和报销政策方面的融合变革进行了实用性综述。

在治疗方法、分析技术和医疗服务模式创新推动下，郁血性的心臟衰竭格局正在改变。药物研发的进步，例如调节神经激素通路药物的扩展以及具有血糖控制以外作用的新兴药物类别，正在改变第一线治疗和联合治疗策略。同时，器械治疗也在从单一矫正装置发展到能够实现同步起搏、预防心律不整和生理监测的整合系统，从而支持更具适应性和个人化的治疗管理。

对影响心臟衰竭药物和医疗设备供应链的新关税措施的运营、采购和患者获取方面的影响进行战略评估

2025年生效的新关税可能会重塑与心臟衰竭治疗及相关器械相关的供应链经济格局、采购行为和战略采购决策。对原料、电子元件和成品医疗设备征收更高的关税，可能会增加依赖全球组装和零件采购的器材製造商的到岸成本。为应对这一变化，製造商可能会加快生产回流，扩大其区域製造地，或重新谈判供应商合同，以缓解利润压缩并确保关键零部件的供应。

将治疗方法、疾病亚型、临床环境和给药方式与临床应用驱动因素和商业化策略联繫起来的详细細項分析

对郁血性心臟衰竭领域进行细分，有助于明确临床需求、商业性机会和技术主导差异化之间的交集。治疗方法涵盖器械治疗、药物治疗和外科手术，每种疗法都有其独特的决策因素和证据要求。在器械治疗方面，心臟再同步化治疗和植入式心臟整流去颤器等技术越来越重视封闭回路型感知、电池寿命以及与远端监测平台的兼容性。药物类别包括血管紧张素转换酶抑制剂、醛固酮拮抗剂、血管收缩素II受体阻断剂、 β阻断剂、利尿剂以及一系列除血糖控制外还能带来心血管获益的新型药物。对药物耐受性、依从性和製剂创新的比较评估会影响处方模式和指南的更广泛应用。冠状动脉绕道手术手术、瓣膜修復术和心室辅助装置等外科手术对于晚期患者仍然至关重要，随着手术技术的改进和手术全期管理的优化，患者的生存率和康復情况也在不断提高。

美洲、欧洲、中东和非洲以及亚太地区在技术采纳和监管方面的差异，将决定临床创新能否转化为永续的商业性效益。

受不同管理体制、报销模式和医疗基础设施的影响，区域趋势正在推动该地区加速投资、创新和应用。在美洲，活跃的临床试验、成熟的公私支付方体係以及较高的医院采纳率，共同为那些疗效显着且能节省成本的医疗设备和药物创造了有利条件。北美医疗中心往往是医疗设备创新和大型多中心试验的早期采用者，这些试验会影响全部区域的指南更新和支付方决策。

企业策略和跨部门合作优先考虑整合医疗设备、药品和数位化解决提案，以满足临床需求和支付方的价值标准。

郁血性心臟衰竭领域的主要企业正在调整其研发、伙伴关係和商业策略，以平衡短期市场准入挑战与长期差异化发展。现有製药公司持续优化其以神经激素调节和辅助性治疗为核心的产品组合策略，而生物製药参与企业致力于探索独特的药物作用机制、提高耐受性以及与数位化药物管理工具的整合。医疗设备製造商正投资于硬体的迭代改进和软体服务，以增强远端监测、电池效率和演算法心律不整检测能力，从而建立整合式医疗生态系统，而非仅仅销售独立的硬体。

为加速推广应用并维持临床影响，提出切实可行的经营团队建议，旨在将综合证据产生、多元化供应链和基本契约连结起来。

产业领导者应采取果断措施，使临床创新与商业性可行性和系统层面的价值创造相契合。首先，应优先进行整合证据项目，将随机数据与实际应用的真实世界证据相结合，从而同时满足临床医生、支付方和监管机构的需求。以病人为中心的研究设计将缩短商业化週期，并有助于医保报销谈判。其次，应投资模组化生产和区域供应多元化，以降低关税和物流风险，同时加快大型医院和医疗系统对采购週期的反应。

为了支持我们的策略洞察力，我们采用透明、多方面的调查方法，整合临床证据审查、专家访谈、供应链分析和监管资讯分析。

本分析的调查方法结合了多源证据综合、专家相关人员对话以及临床和商业资料流的三角验证。我们对同行评审的临床文献、监管申报文件和主要指南修订进行了全面审查，以确定检验的作用机制和医疗设备效能指标。此外，我们也咨询了执业心臟病专家、介入外科医生、医院采购人员和生命科学公司高管，以了解临床实践中的决策驱动因素和应用障碍，从而进一步完善了临床基础。

一份简明扼要的综述强调，整合证据、供应链韧性和伙伴关係主导的商业化是实现心臟衰竭治疗持续改善的途径。

总之，郁血性心臟衰竭领域正处于一个转折点，治疗方法创新、医疗设备的日益精进和数位化医疗模式与不断变化的政策和采购趋势交织在一起。产业和临床相关人员的成功将取决于能否获得可靠、多方面的证据，能否设计出互通性和以患者为中心的医疗技术，以及能否建立符合支付方对有效治疗效果要求的商业性模式。供应链的韧性和区域製造策略可能会影响近期的医疗服务可近性，尤其是在关税和贸易不确定性的情况下。同时，合作式的商业模式可以降低推广门槛，加速规模化应用。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • SGLT2抑制剂在心臟衰竭中的广泛应用可降低住院率并提高存活率
  • 用于预测风险分层和个人化心臟衰竭治疗策略的新兴人工智慧平台
  • 整合远端患者监护设备，以收集即时血流动力学数据并协调干预措施
  • 扩大针对心肌重塑路径基因治疗的研究，以解决慢性心臟衰竭的根本原因。
  • 开发一种联合使用脑啡肽酶抑制剂和血管紧张素受体阻断剂的药物治疗方法，以改善心臟功能
  • 利用远端医疗的跨专业照护模式对于降低心臟衰竭患者的再入院率变得越来越重要。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依治疗类型分類的郁血性心臟衰竭市场

  • 器械疗法
    • 心臟再同步治疗
    • 植入式心臟整流去颤器
  • 药物治疗
    • ACE抑制剂
    • 醛固酮拮抗剂
    • 血管收缩素II受体阻断剂
    • β阻断剂
    • 利尿剂
    • SGLT2抑制剂
  • 手术介入
    • 冠状动脉绕道手术手术
    • 心臟瓣膜修復
    • 心室辅助装置

第九章 依疾病类型分類的郁血性心臟衰竭

  • 急性心臟衰竭
  • 慢性心臟衰竭
  • 左心臟衰竭
    • 舒张性心衰竭
    • 收缩性心臟衰竭
  • 右心臟衰竭

第十章 依最终用户分類的郁血性心臟衰竭市场

  • 医院和诊所
    • 私人诊所
    • 公立医院
  • 研究所

第十一章郁血性心臟衰竭市场（依管理方式）

  • 注射
  • 口服
  • 经皮

第十二章郁血性心臟衰竭市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章郁血性心臟衰竭市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国郁血性心臟衰竭市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbott Laboratories
    • Alnylam Pharmaceuticals, Inc.
    • Amgen Inc.
    • AstraZeneca
    • Bayer AG
    • Becton, Dickinson and Company
    • Biotronik SE & Co. KG
    • Boehringer Ingelheim International GmbH
    • Boston Scientific Corporation
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Medtronic plc
    • Merck & Co., Inc.
    • Novartis AG
    • Otsuka Pharmaceutical Co., Ltd.
    • Pfizer Inc.
    • ResMed Inc.
    • Sanofi Group
    • Servier Laboratories
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-1A1A064C04DC

The Congestive Heart Failure Market is projected to grow by USD 9.62 billion at a CAGR of 7.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.35 billion
Estimated Year [2025] USD 5.73 billion
Forecast Year [2032] USD 9.62 billion
CAGR (%) 7.60%

A strategic framing of the congestive heart failure clinical, technological, and policy drivers shaping care pathways and stakeholder priorities over the near to medium term

Congestive heart failure remains a central challenge for clinicians, health systems, and innovators, driving an urgent need for integrated clinical, technological, and policy responses. Advances in pharmacology, device therapy, and surgical techniques are converging with digital health and remote monitoring to change how patients are diagnosed, stratified, and managed across care settings. At the same time, payer expectations and regulatory scrutiny push stakeholders to demonstrate real-world effectiveness and cost-conscious clinical benefit. This introduction establishes the clinical context, highlights the pivotal technologies and therapeutic classes, and frames the strategic tensions that leaders must navigate to deliver improved outcomes.

Clinicians continue to emphasize earlier detection and more personalized treatment pathways, which has prompted greater attention to biomarkers, imaging innovations, and ambulatory monitoring. Industry players are responding with devices that integrate diagnostics and therapy, medications that target pathophysiologic mechanisms with improved tolerability, and procedural refinements that reduce perioperative risk. Policy and reimbursement environments are responding as well, encouraging outcome-based contracting and pathways that prioritize value over volume. Taken together, these forces require a coordinated response across suppliers, providers, and policy-makers to translate innovation into sustained improvements in morbidity and quality of life for patients living with heart failure.

An actionable review of converging therapeutic, digital, and reimbursement shifts that are redefining patient pathways and commercial imperatives in heart failure care

The landscape for congestive heart failure care is undergoing transformative shifts driven by innovations in therapy, analytics, and care delivery. Pharmacologic advances such as the expansion of agents that modulate neurohormonal pathways and emerging classes that show benefits beyond glycemic control are altering first-line and combination therapy strategies. Simultaneously, device therapy has evolved from discrete corrective devices to integrated systems that enable synchronized pacing, arrhythmia prevention, and physiologic sensing, which supports more adaptive and individualized management.

Digital health and remote monitoring catalyze earlier intervention and reduce avoidable hospital encounters by enabling continuous physiologic assessment and prompt clinical triage. These capabilities are reshaping care pathways from episodic to longitudinal models and shifting the locus of care toward ambulatory settings and virtual platforms. At the same time, health policy trends toward value-based contracting and outcome-linked reimbursement place sustained emphasis on demonstrating meaningful clinical benefit and lowering total cost of care. Together, these shifts create new commercial imperatives for clinical evidence generation, interoperability, patient engagement strategies, and supply chain resilience.

A strategic assessment of the operational, procurement, and patient access consequences driven by new tariff measures affecting heart failure therapeutics and device supply chains

The introduction of new tariff measures in 2025 has the potential to reconfigure supply chain economics, procurement behavior, and strategic sourcing decisions relevant to heart failure therapies and supporting devices. Tariff increases on raw materials, electronic components, and finished medical devices can raise landed costs for device manufacturers who rely on globalized assembly and component sourcing. In response, manufacturers may accelerate onshoring, expand regional manufacturing footprints, or renegotiate supplier contracts to mitigate margin compression and preserve access to critical components.

Health systems and hospital procurement teams can experience immediate budgetary pressure as device acquisition costs rise, which often triggers more stringent evaluation protocols, extended tender cycles, and an increased focus on total cost of ownership. Payers and integrated delivery networks could push for price concessions or demand stronger evidence of durability and real-world outcomes before approving capital purchases. At the same time, tariff-driven cost inflation may incentivize local suppliers and smaller manufacturers to capture niche opportunities, particularly for components and consumables where domestic capacity can scale quickly. Policymakers and industry leaders will need to collaborate on tariff exemptions for critical medical supplies, strategic stockpiling, and trade dialogues to avoid unintended disruptions to clinical care and to maintain continuity of treatment for vulnerable patients.

Granular segmentation insights that connect therapeutic modalities, disease subtypes, care settings, and delivery formats to clinical adoption drivers and commercialization strategies

Segmenting the congestive heart failure landscape clarifies where clinical need intersects with commercial opportunity and technology-driven differentiation. Treatment types span device therapy, medication, and surgical intervention, each with distinct decision drivers and evidence requirements. Within device therapy, technologies that deliver cardiac resynchronization and those that provide implantable cardioversion increasingly emphasize closed-loop sensing, battery longevity, and compatibility with remote interrogation platforms. Medication classes include ACE inhibitors, aldosterone antagonists, angiotensin II receptor blockers, beta blockers, diuretics, and the newer class of agents that confer cardiovascular benefit beyond glycemic control; comparative tolerability, adherence, and formulation innovation influence prescribing patterns and broader guideline uptake. Surgical interventions such as coronary artery bypass grafting, valve repair, and ventricular assist devices remain essential for advanced disease, and procedural refinement plus perioperative optimization continues to improve survival and recovery trajectories.

Disease-type stratification is equally consequential, with acute and chronic heart failure presenting different care pathways and resource intensities. Left-sided heart failure, encompassing both diastolic and systolic dysfunction, often requires nuanced pharmacologic and device strategies tailored to ejection fraction status, while right-sided heart failure presents unique hemodynamic and comorbidity challenges that influence therapeutic choices. End-user segmentation identifies hospitals and clinics alongside research institutes as primary adoption channels; within hospitals and clinics, private and public institutions navigate different procurement rules, budget cycles, and adoption thresholds that affect how new therapies and devices scale. Delivery methods-injectable, oral, and transdermal-introduce formulation and adherence considerations that shape patient acceptance and long-term regimen persistence. Integrating these segmentation lenses supports targeted clinical evidence generation, differentiated value propositions for payers, and market access approaches that align with care setting realities.

Regional adoption and regulatory contrasts across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine where clinical innovation translates into sustainable commercial traction

Regional dynamics shape where investment, innovation, and adoption accelerate, driven by differing regulatory regimes, reimbursement models, and care infrastructures. In the Americas, robust clinical trial activity, a mature private and public payer mix, and high hospital adoption rates create fertile ground for devices and pharmaceuticals that demonstrate definitive outcome improvements and cost offsets. North American centers often serve as early adopters for device-based innovation and large multicenter trials, which in turn inform guideline updates and payer decisions across the region.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization efforts coexist with diverse reimbursement environments. Western European markets typically emphasize health technology assessment and strong post-market surveillance, which favors innovations with clear comparative effectiveness data. Emerging markets within the broader region may prioritize cost-effective interventions and scalable delivery models, creating opportunities for lower-cost devices, simplified delivery methods, and task-shifting strategies that extend specialist care into community settings.

Asia-Pacific exhibits rapid growth in both clinical capacity and local manufacturing capabilities, coupled with increasing public investment in cardiovascular infrastructure. Many health systems in the region emphasize scalable solutions that address large patient volumes and workforce constraints, driving interest in remote monitoring, minimally invasive procedures, and oral therapeutic regimens that require fewer specialist touchpoints. Regulatory pathways in several Asia-Pacific markets have also shortened approval timelines for breakthrough technologies, encouraging quick market entry when companies can demonstrate robust clinical benefit and adaptability to local care models.

Company strategies and cross-sector collaborations that prioritize integrated device, pharmaceutical, and digital propositions to meet clinical demands and payer value criteria

Key companies operating across the congestive heart failure landscape are aligning R&D, partnerships, and commercial strategies to balance near-term access challenges with long-term differentiation. Established pharmaceutical firms continue to refine portfolio strategies around neurohormonal modulation and adjunctive therapies, while biopharma entrants pursue niche mechanisms and improved tolerability profiles that can be paired with digital adherence tools. Device manufacturers are investing in iterative hardware improvements and software-enabled services that enhance remote monitoring, battery efficiency, and algorithmic arrhythmia detection, thereby creating integrated care ecosystems rather than standalone hardware sales.

Collaborative models between device makers, pharmaceutical companies, and technology vendors are increasingly common, reflecting the need to bundle clinical evidence and service offerings that demonstrate measurable reductions in hospital admissions and improved patient-reported outcomes. Mergers, selective licensing agreements, and strategic alliances focus on accelerating regulatory submissions, expanding geographic reach, and combining complementary technologies, especially where cross-disciplinary integration delivers a clear clinical advantage. For many organizations, the strategic playbook prioritizes scalable solutions that meet payer expectations for value and providers' demand for ease of integration into existing workflows.

Actionable executive recommendations that connect integrated evidence generation, diversified supply chains, and value-based contracting to accelerate adoption and sustain clinical impact

Industry leaders should take decisive steps to align clinical innovation with commercial viability and system-level value creation. First, prioritize integrated evidence programs that combine randomized data with pragmatic real-world evidence to satisfy clinicians, payers, and regulators simultaneously; designing studies that capture patient-centered outcomes will shorten commercialization timelines and support reimbursement discussions. Second, invest in modular manufacturing and regional supply diversification to reduce tariff and logistics exposure while enabling faster response to procurement cycles in key hospitals and health systems.

Third, forge strategic partnerships that unite device interoperability, pharmacologic optimization, and digital engagement to offer bundled solutions which demonstrably reduce readmissions and improve functional status. Fourth, adopt flexible pricing and contracting frameworks, including outcome-linked agreements, to bridge adoption gaps in cost-sensitive settings and to share risk with payers. Fifth, accelerate deployment of remote monitoring and telehealth-enabled care pathways to shift care upstream and reduce acute episode frequency; this requires investment in clinician training and seamless integration with electronic health records. Finally, maintain a disciplined focus on health economics and value communication so that product teams can articulate total cost of care benefits to hospitals, integrated delivery networks, and national health authorities.

A transparent and multi-source research methodology integrating clinical evidence review, expert interviews, supply chain analysis, and regulatory intelligence to underpin strategic findings

The research methodology underpinning this analysis combined multi-source evidence synthesis, expert stakeholder engagement, and triangulation across clinical and commercial data streams. We performed an exhaustive review of peer-reviewed clinical literature, regulatory filings, and major guideline updates to identify validated therapeutic mechanisms and device performance metrics. This clinical foundation was enriched by consultations with practicing cardiologists, interventional surgeons, hospital procurement leaders, and life-science executives to capture decision-making drivers and adoption barriers across care settings.

Operational intelligence incorporated an assessment of manufacturing and supply chain structures, procurement practices, and policy developments relevant to tariffs and trade. Where possible, clinical trial registries and public safety databases provided orthogonal validation of device performance characteristics and adverse event profiles. All qualitative inputs were cross-checked against published clinical endpoints and regulatory milestones to ensure accuracy, and the resulting insights were stress-tested through scenario analysis to evaluate the implications of policy shifts, reimbursement changes, and technology adoption curves.

A concise synthesis emphasizing integrated evidence, supply resilience, and partnership-driven commercialization as the pathways to durable improvements in heart failure care

In conclusion, the congestive heart failure landscape is at an inflection point where therapeutic innovation, device sophistication, and digital care models intersect with evolving policy and procurement dynamics. Success for industry and clinical stakeholders depends on generating robust, multi-dimensional evidence; designing interoperable and patient-centric technologies; and structuring commercial approaches that align with payer demands for meaningful outcomes. Supply chain resilience and regional manufacturing strategies will influence near-term access, particularly in the face of tariff and trade uncertainty, while collaborative commercial models can lower adoption barriers and accelerate scale.

Moving forward, organizations that integrate clinical, operational, and commercial disciplines will capture the greatest value while improving patient outcomes. A disciplined focus on health economic evidence, targeted regional strategies, and partnerships that bundle technology with services will enable sustainable adoption. Ultimately, the path to better care for patients with congestive heart failure requires coordination across research, clinical practice, and health system leadership to translate innovation into accessible, durable improvement in clinical and quality-of-life metrics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing utilization of SGLT2 inhibitors in heart failure to reduce hospitalizations and improve survival rates
  • 5.2. Emerging artificial intelligence platforms for predictive risk stratification and personalized heart failure treatment strategies
  • 5.3. Integration of remote patient monitoring devices enabling real time hemodynamic data collection and intervention adjustments
  • 5.4. Expansion of gene therapy research targeting myocardial remodeling pathways to address underlying causes of chronic heart failure
  • 5.5. Development of combination pharmacotherapy approaches combining neprilysin inhibitors with ARBs for enhanced cardiac function
  • 5.6. Increasing emphasis on telehealth enabled multidisciplinary care models to reduce readmission rates in heart failure populations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Congestive Heart Failure Market, by Treatment Type

  • 8.1. Device Therapy
    • 8.1.1. Cardiac Resynchronization Therapy
    • 8.1.2. Implantable Cardioverter Defibrillators
  • 8.2. Medication
    • 8.2.1. ACE Inhibitors
    • 8.2.2. Aldosterone Antagonists
    • 8.2.3. Angiotensin II Receptor Blockers
    • 8.2.4. Beta Blockers
    • 8.2.5. Diuretics
    • 8.2.6. SGLT2 Inhibitors
  • 8.3. Surgical Intervention
    • 8.3.1. Coronary Artery Bypass Grafting
    • 8.3.2. Heart Valve Repair
    • 8.3.3. Ventricular Assist Devices

9. Congestive Heart Failure Market, by Disease Type

  • 9.1. Acute Heart Failure
  • 9.2. Chronic Heart Failure
  • 9.3. Left-Sided Heart Failure
    • 9.3.1. Diastolic Heart Failure
    • 9.3.2. Systolic Heart Failure
  • 9.4. Right-Sided Heart Failure

10. Congestive Heart Failure Market, by End User

  • 10.1. Hospitals and Clinics
    • 10.1.1. Private Clinics
    • 10.1.2. Public Hospitals
  • 10.2. Research Institutes

11. Congestive Heart Failure Market, by Delivery Methods

  • 11.1. Injectable
  • 11.2. Oral
  • 11.3. Transdermal

12. Congestive Heart Failure Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Congestive Heart Failure Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Congestive Heart Failure Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. Alnylam Pharmaceuticals, Inc.
    • 15.3.3. Amgen Inc.
    • 15.3.4. AstraZeneca
    • 15.3.5. Bayer AG
    • 15.3.6. Becton, Dickinson and Company
    • 15.3.7. Biotronik SE & Co. KG
    • 15.3.8. Boehringer Ingelheim International GmbH
    • 15.3.9. Boston Scientific Corporation
    • 15.3.10. Bristol-Myers Squibb Company
    • 15.3.11. Eli Lilly and Company
    • 15.3.12. F. Hoffmann-La Roche AG
    • 15.3.13. Gilead Sciences, Inc.
    • 15.3.14. GlaxoSmithKline plc
    • 15.3.15. Johnson & Johnson
    • 15.3.16. Medtronic plc
    • 15.3.17. Merck & Co., Inc.
    • 15.3.18. Novartis AG
    • 15.3.19. Otsuka Pharmaceutical Co., Ltd.
    • 15.3.20. Pfizer Inc.
    • 15.3.21. ResMed Inc.
    • 15.3.22. Sanofi Group
    • 15.3.23. Servier Laboratories
    • 15.3.24. Takeda Pharmaceutical Company Limited
    • 15.3.25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CONGESTIVE HEART FAILURE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CONGESTIVE HEART FAILURE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CONGESTIVE HEART FAILURE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIURETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIURETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIURETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIURETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIURETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIURETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HEART VALVE REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HEART VALVE REPAIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HEART VALVE REPAIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HEART VALVE REPAIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HEART VALVE REPAIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HEART VALVE REPAIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACUTE HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACUTE HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACUTE HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACUTE HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACUTE HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACUTE HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CHRONIC HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CHRONIC HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CHRONIC HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CHRONIC HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CHRONIC HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CHRONIC HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIASTOLIC HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIASTOLIC HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIASTOLIC HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIASTOLIC HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIASTOLIC HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIASTOLIC HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SYSTOLIC HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SYSTOLIC HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SYSTOLIC HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SYSTOLIC HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SYSTOLIC HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SYSTOLIC HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)